Biotech Startups

1 investor

Instance produces large-scale functional biological data intended for AI-driven biology and biological engineering, letting customers submit designs and receive functional data for their specific learning objectives.

1 investor

Instem provides SaaS platforms and services for research and development in the life sciences industry, serving pharmaceutical companies, CROs, CDMOs, academic research institutions, biotechnology firms, industrial organizations, and agrichemical companies.

1 investor

1 investor

Intactis Bio develops a rack-mountable AI accelerator, the Biohybrid Processing Unit (BPU), that combines silicon processors with lab-grown living neurons and a brain-machine interface to run energy-efficient AI/ML data processing. The company positions its biocomputation platform for data centers and high-performance workloads, with applications in AI and drug discovery.

1 investor

Intas is a vertically integrated global pharmaceutical company engaged in formulation development, manufacturing, and marketing of pharmaceuticals across more than 85 countries. The company operates through Accord Healthcare subsidiaries in major markets and invests in biosimilars and new chemical entities.

1 investor

InTech Medical (operating as EXALTA) provides turnkey OEM manufacturing and engineering solutions for medical devices, primarily serving orthopedic and surgical device companies from concept through regulatory clearance and production launch. The company offers integrated design, regulatory, and manufacturing services with a global footprint.

1 investor

Integrated Dynamics develops high-temperature fermentation technology to produce bio-based chemical intermediates for onshore manufacturing. The company's solutions integrate into new or existing industrial fermentation infrastructure to reduce production costs.

1 investor

Integrated Nanotherapeutics develops lipid nanoparticle science and drug formulations for therapeutic applications. The company is led by scientists with over 100 years of collective expertise in preclinical research and drug development.

1 investor

Integrated Biosciences is a biotech company developing treatments and interventions for aging-related diseases using a combination of medicinal chemistry, biochemistry, aging biology, and artificial intelligence.

1 investor

IntegriChain provides a data platform that helps biopharmaceutical companies optimize net revenue performance and ensure patient access to therapies. The company serves established and emerging biopharma manufacturers by managing pricing, rebates, claims, and patient data across their commercial operations.

1 investor

InterAx Biotech develops computational and structural biology tools for pharmaceutical research and drug discovery, serving biopharmaceutical companies and researchers in drug development.

1 investor

1 investor

Interna develops a molecular delivery platform that transports large molecule therapeutics such as DNA, RNA, and proteins across cell membranes to treat infectious and non-infectious diseases. The company's molecular nano-motor technology harnesses the cell membrane's electric potential to enable intracellular drug delivery for respiratory and other therapeutic applications.

1 investor

LIC is a farmer-owned cooperative that develops and exports dairy genetics for artificial insemination, serving dairy farmers in New Zealand and 20 countries globally to improve herd productivity and profitability.

1 investor

Interpace Biosciences provides molecular diagnostic tests for the early diagnosis and treatment of cancer, with a focus on risk-stratifying indeterminate thyroid nodules through genetic and mutational analysis. The company serves specialty physicians and medical centers in the U.S. and internationally.

1 investor

Intervacc develops veterinary vaccines based on recombinant protein fusions. The company's lead product, Strangvac®, prevents strangles in horses, a serious and contagious global disease, and is available on several major European markets.

1 investor

Intragel is developing SRGel, a solvent-free long-acting injectable (LAI) drug delivery platform designed to enable controlled, extended release from a single injection for small molecules, peptides and biologics. The platform aims to extend dosing intervals and reduce injection frequency across multiple therapeutic areas.

1 investor

A biopharmaceutical company developing treatments for psychiatric and neurologic disorders based on research into how therapies affect cellular mechanisms. The company, now part of Johnson & Johnson, focuses on innovative therapies for patients with complex brain-related diseases.

1 investor

Intrepid Labs applies active machine learning, robotics, and pharmaceutical science to accelerate the design and development of drug products and delivery formulations. It uses a closed-loop platform to develop next-generation therapeutics with improved properties and performance.

1 investor

Intron Biotechnology is a South Korean biotech company developing novel drugs based on bacteriophage platform technology, including "First-in-Class" treatments for multidrug-resistant superbacteria and "First-in-Concept" therapeutics targeting microbiome, viruses, and immune modulation. It positions itself as a global R&BD group in the biopharmaceutical field.

1 investor

Intus Bio develops Titan-1, a microbiome analysis technology that combines long-read sequencing, patented science, and AI to produce higher-resolution microbiome data than shotgun metagenomic and 16S approaches. It applies these insights to biomarker discovery, drug development, and patient testing across healthcare.

1 investor

Invasive Species Corporation develops biological solutions to control invasive species and resistant pests across agriculture, water management, and environmental sectors. The company combines expertise in microbial discovery and product development to deliver environmentally friendly alternatives to traditional pest management.

1 investor

Invea Therapeutics is a biotechnology company developing oral small molecule therapies for immune-mediated inflammatory diseases (IMIDs), using artificial intelligence and machine learning to study inflammation mechanisms such as mast cell and inflammasome biology. It targets both common and rare IMIDs to serve patients with chronic inflammatory conditions.

1 investor